methyl 7-chloro-6-oxoheptanoate | 69378-72-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 7-chloro-6-oxoheptanoate
• CAS: 69378-72-9
• 化学式: C₈H₁₃ClO₃
• 分子量: 192.642
• InChiKey: HISQZAFLADECBN-UHFFFAOYSA-N

物化性质

• 沸点：
  268.7±20.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 7-chloro-6-oxoheptanoate 在 三乙胺 、 sodium hydroxide 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 N-[4-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3-thiazol-2-yl]-2-phenylacetamide
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors

  摘要：

  Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenylacetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.

  DOI：

  10.1021/jm301191p
• 作为产物：
  描述：

  6-氧代庚酸甲酯 生成 methyl 7-chloro-6-oxoheptanoate
  参考文献：
  名称：

  GRIESBAUM, KARL, ERDOL UND KOHLE-ERDGAS-PETROCHEM., 42,(1989) N, C. 19-21

  摘要：

  DOI：

文献信息

• Haloalkylguanidine compounds, pharmaceutical compositions and methods,
  申请人：Imperial Chemical Industries PLC

  公开号：US04447441A1

  公开（公告）日：1984-05-08

  The invention relates to guanidine derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I:- ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.5 --E--W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O,S or NR.sup.6 in which R.sup.6 is H or 1-6C alkyl, R.sup.5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.5 and R.sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; D is O or S; and R.sup.3 and R.sup.4 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  该发明涉及胍基衍生物，它们是组胺H-2拮抗剂，能抑制胃酸分泌。根据该发明，提供了一种符合以下式I的胍基衍生物：- ##STR1## 其中R.sup.1和R.sup.2，相同或不同，是氢或1-10碳原子的烷基，3-8碳原子的环烷基或4-14碳原子的环烷基烷基，每个烷基、环烷基或环烷基烷基可选地携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个是卤素取代的，或者R.sup.2是氢而R.sup.1是R.sup.5--E--W，其中W是可选地由1或2个1-4碳原子的烷基取代的2-6碳原子的亚烷基，E是O、S或NR.sup.6，其中R.sup.6是H或1-6碳原子的烷基，R.sup.5是H或1-6碳原子的烷基，可选地由1或2个1-4碳原子的烷基取代，或者R.sup.5和R.sup.6连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环；环X是规范中定义的杂环；A是苯基或5-7碳原子的环烷基，或者可选地插入一到两个基团的1-8碳原子的亚烷基；D是O或S；R.sup.3和R.sup.4是氢或规范中描述的各种基团；以及其药用可接受的酸加盐。还描述了制造工艺和药物组合物。
• Thiazolo[3,4-b]isoquinolines
  申请人：Rhone Poulenc Industries

  公开号：US04363909A1

  公开（公告）日：1982-12-14

  Isoquinoline derivatives of the formula ##STR1## wherein the symbol A.sub.1 represents an isoquinol-8-yl, 3-methylisoquinol-8-yl, 3-hydroxymethylisoquinol-5-yl, 3-carboxymethylisoquinol-5-yl, quinol-5-yl, thienopyridyl, benzimidazolyl, thienyl or thiazolyl radical, a 4-(or 5-)carboxyalkylthiazol-2-yl radical in which the alkyl moiety is linear or branched and contains 1 to 4 carbon atoms, or a 1,3,4-thiadiazol-2-yl, pyrazolyl, imidazolyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, monocyclic heterocyclic rings within the definition of A.sub.1 being optionally substituted by a linear or branched alkyl radical containing 1 to 4 carbon atoms, in the (S) or (R,S) form or mixtures thereof, and salts thereof possess useful pharmocological properties, in particular antiviral activity.

  公式为##STR1##的异喹啉衍生物，其中符号A.sub.1代表异喹啉-8-基、3-甲基异喹啉-8-基、3-羟甲基异喹啉-5-基、3-羧甲基异喹啉-5-基、喹啉-5-基、噻吩吡啶基、苯并咪唑基、噻吩基或噻唑基基团，一种4-(或5-)羧基烷基噻唑-2-基基团，其中烷基部分是直链或支链且含有1至4个碳原子，或者是1,3,4-噻二唑-2-基、吡唑基、咪唑基、嘧啶基、吡啶嗪基或吡啶基基团，A.sub.1定义内的单环杂环环可选择地被含有1至4个碳原子的直链或支链烷基基团取代，以(S)或(R,S)形式或它们的混合物，以及其盐具有有用的药理特性，特别是抗病毒活性。
• Synthesis of aliphatic α-ketoamides from α-substituted methyl ketones <i>via</i> a Cu-catalyzed aerobic oxidative amidation
  作者：Hyojin Cha、Jin Young Chai、Hyeong Baik Kim、Dae Yoon Chi

  DOI：10.1039/d1ob00129a

  日期：——

  for making aryl α-ketoamides as drug candidates have been greatly improved through metal-catalyzed aerobic oxidative amidations. However, the preparation of alkyl α-ketoamides through metal-catalyzed aerobic oxidative amidations has not been reported because generating α-ketoamides from aliphatic ketones with two α-carbons theoretically provides two distinct α-ketoamides. Our strategy is to activate

  α-酮酰胺是一个重要的关键官能团，已被用作多种官能团转化中的通用且有价值的中间体和合成子。通过金属催化的好氧氧化酰胺化，制备芳基α-酮酰胺作为候选药物的合成方法得到了极大的改进。然而，尚未报道通过金属催化的需氧氧化酰胺化制备烷基α-酮酰胺，因为从理论上具有两个α-碳的脂肪族酮生成α-酮酰胺提供了两种不同的α-酮酰胺。我们的策略是通过引入N来激活 α-碳-在两个α位之一的取代基。该策略的关键是杂环化合物如三唑和咪唑如何影响烷基α-酮酰胺合成的选择性。从这个基本概念出发，通过优化反应和阐明通过铜催化的好氧氧化酰胺化合成芳基 α-酮酰胺的机理，我们以高产率（48-84%）制备了 14 种脂肪族 α-酮酰胺。
• Imidazole compounds and their use as transglutaminase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US05077285A1

  公开（公告）日：1991-12-31

  Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.

  本发明公开了包括咪唑和咪唑盐在内的咪唑化合物，并将其用作转谷氨酰胺酶抑制剂。
• Guanidine derivatives
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0060094A2

  公开（公告）日：1982-09-15

  The invention relates to guanidine derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention where is provided a guanidine derivative of the formula I:- in which R' and R2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F. Cl or Br atoms, provided that one of R' and R2 is halogen substituted, or R2 is hydrogen and R' is R5-E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O,S or NR5 in which R6 is H or 1-6C alkyl, R5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R5 and R6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring;t ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-SC alkylene into which is optionally inserted one or two groups; D is 0 or S; and R3 and R4 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及组胺 H-2 拮抗剂和抑制胃酸分泌的胍衍生物。根据本发明提供了一种式 I 的胍衍生物 其中R'和R2，相同或不同，为氢或1-10C烷基、3-8C环烷基或4-14C环烷基烷基，每个烷基、环烷基或环烷基烷基可选带一个或多个F.Cl或Br原子，条件是R'和R2中的一个被卤素取代，或R2是氢，R'是R5-E-W，其中W是任选被1或2个1-4C烷基取代的2-6C亚烷基，E是O、S或NR5，其中R6是H或1-6C烷基，R5是H或任选被1或2个1-4C烷基取代的1-6C烷基，或R5和R6连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环；t 环 X 是本说明书中定义的杂环；A 是亚苯基或 5-7C 环亚烷基，或 1-SC 亚烷基，其中可选择插入一个或两个基团；D 是 0 或 S；R3 和 R4 是氢或本说明书中描述的各种基：及其药学上可接受的酸加成盐。还描述了制造工艺和药物组合物。